ONGLYZA® (saxagliptin)

How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?

Onglyza: Clinically relevant HbA1c reductions in patients with renal impairment vs placebo

In patients with moderate to severe renal impairment, Onglyza 2.5 mg resulted in :

Clinically relevant HbA1C reductions in patients with renal impairment vs placebo
Clinically relevant HbA1C reductions in patients with renal impairment vs placebo

1. Nowicki M et al. Int J Clin Pract 2011; 65; 1230-1239.
2. Nowicki M et al. Diabetes Obes Metab 2011; 13: 523-532.